Analyst Activity – FinnCap Reiterates Corporate on Synairgen plc (LON:SNG)

Analyst Ratings For Synairgen plc (LON:SNG)

Story continues below

Today, FinnCap reiterated its Corporate rating on Synairgen plc (LON:SNG) with a price target of GBX 137.

There are 1 buy rating on the stock.

The current consensus rating on Synairgen plc (LON:SNG) is Buy (Score: 3.00) with a consensus target price of GBX 91.50 per share, a potential .

Some recent analyst ratings include

  • 2/24/2017-FinnCap Reiterated Rating of Corporate.

    About Synairgen plc (LON:SNG)
    Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company’s primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company’s subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

    Recent Trading Activity for Synairgen plc (LON:SNG)
    Shares of Synairgen plc closed the previous trading session at 25.00 down -0.50 -1.96% with 0 shares trading hands.

    An ad to help with our costs